Does RIPRETINIB Cause Malignant neoplasm progression? 105 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 105 reports of Malignant neoplasm progression have been filed in association with RIPRETINIB (QINLOCK). This represents 2.4% of all adverse event reports for RIPRETINIB.
105
Reports of Malignant neoplasm progression with RIPRETINIB
2.4%
of all RIPRETINIB reports
17
Deaths
42
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RIPRETINIB?
Of the 105 reports, 17 (16.2%) resulted in death, 42 (40.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 105 reports have been filed with the FAERS database.
What Other Side Effects Does RIPRETINIB Cause?
Fatigue (582)
Alopecia (517)
Extra dose administered (357)
Death (356)
Underdose (345)
Nausea (292)
Drug ineffective (291)
Disease progression (290)
Hospitalisation (280)
Neoplasm progression (263)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RIPRETINIB Alternatives Have Lower Malignant neoplasm progression Risk?
RIPRETINIB vs RISANKIZUMAB
RIPRETINIB vs RISANKIZUMAB-RZAA
RIPRETINIB vs RISDIPLAM
RIPRETINIB vs RISEDRONATE
RIPRETINIB vs RISEDRONIC ACID